GlassScriptPhysician profile
Mahmood Alam
NPI 1083669741
$6,777.63
in general payments reported to CMS, 2019-2025
30 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $479 · 2021: $778 · 2022: $1,001 · 2023: $1,090 · 2024: $953 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $1,504.08 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Glaxosmithkline, LLC. | $1,471.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $928.65 | 2020-2025 | Aralast, Glassia, Cuvitru |
| Genzyme Corporation | $319.93 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.93 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $278.29 | 2019-2025 | Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $233.37 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $205.83 | 2021-2024 | Yupelri |
| Shire North American Group INC | $205.40 | 2019 | |
| Mallinckrodt Hospital Products INC. | $189.39 | 2022-2023 | Acthar |
| Viatris Specialty LLC | $166.82 | 2025 | Yupelri |
| Insmed, INC. | $155.81 | 2019-2025 | Arikayce |
| Amgen INC. | $136.73 | 2019-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $118.24 | 2019 | |
| Genentech USA, INC. | $99.99 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $82.25 | 2025 | Ohtuvayre |
| Philips North America LLC | $74.87 | 2025 | Vest Therapy Und |
| Cleerly, INC. | $55.02 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Vifor Pharma, INC. | $48.67 | 2024-2025 | Zemaira |
| Baxter Healthcare | $32.56 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Bio Products Laboratory USA, INC. | $25.10 | 2021 | |
| Pulmonx Corporation | $22.43 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Electromed, INC. | $22.18 | 2024 | Smartvest |
| Adma Biomanufacturing LLC | $18.28 | 2021 | |
| Insulet Corporation | $15.89 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.03 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.36 | 2019 | |
| United Therapeutics Corporation | $13.74 | 2024 | Tyvaso |
| Circassia INC. | $11.66 | 2019 | |
| Pfizer INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmood Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.